Anaplastic Thyroid Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Anaplastic Thyroid Cancer - Pipeline Review, H2 2016

Anaplastic Thyroid Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Anaplastic Thyroid Cancer - Pipeline Review, H2 2016
Published Jul 20, 2016
73 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Anaplastic Thyroid Cancer - Pipeline Review, H2 2016, provides an overview of the Anaplastic Thyroid Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anaplastic Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anaplastic Thyroid Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer
- The report reviews pipeline therapeutics for Anaplastic Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anaplastic Thyroid Cancer therapeutics and enlists all their major and minor projects
- The report assesses Anaplastic Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anaplastic Thyroid Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline proje

  
Source:
Document ID
GMDHC8246IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Anaplastic Thyroid Cancer Overview71
Therapeutics Development82
  Pipeline Products for Anaplastic Thyroid Cancer Overview81
  Pipeline Products for Anaplastic Thyroid Cancer Comparative Analysis91
Anaplastic Thyroid Cancer Therapeutics under Development by Companies101
Anaplastic Thyroid Cancer Therapeutics under Investigation by Universities/Institutes111
Anaplastic Thyroid Cancer Pipeline Products Glance122
  Clinical Stage Products121
  Early Stage Products131
Anaplastic Thyroid Cancer Products under Development by Companies141
Anaplastic Thyroid Cancer Products under Investigation by Universities/Institutes151
Anaplastic Thyroid Cancer Companies Involved in Therapeutics Development168
  Daiichi Sankyo Company, Limited161
  Genelux Corporation171
  Immune Pharmaceuticals Inc.181
  Millennium Pharmaceuticals Inc191
  Novartis AG201
  Pfizer Inc.211
  Plexxikon Inc.221
  Trophogen, Inc.231
Anaplastic Thyroid Cancer Therapeutics Assessment2410
  Assessment by Monotherapy Products241
  Assessment by Combination Products251
  Assessment by Target262
  Assessment by Mechanism of Action282
  Assessment by Route of Administration302
  Assessment by Molecule Type322
Drug Profiles3436
  ceritinib Drug Profile345
  CLM-3 Drug Profile391
  crizotinib Drug Profile407
  crolibulin Drug Profile472
  dabrafenib mesylate + trametinib dimethyl sulfoxide Drug Profile496
  efatutazone Drug Profile552
  GLONC-2 Drug Profile571
  GLV-1h153 Drug Profile581
  pexidartinib Drug Profile594
  PLX-8394 Drug Profile631
  Recombinant Protein to Antagonize VEGF and PDGF for Anaplastic Thyroid Cancer and Wound Healing Drug Profile641
  sapanisertib Drug Profile653
  utomilumab Drug Profile682
Anaplastic Thyroid Cancer Dormant Projects701
Anaplastic Thyroid Cancer Product Development Milestones711
  Featured News &Press Releases711
    Apr 18, 2013: Combination Therapy Shows Promise Against Anaplastic Thyroid Cancer, Study Finds711
Appendix722
  Methodology721
  Coverage721
  Secondary Research721
  Primary Research721
  Expert Panel Validation721
  Contact Us721
  Disclaimer731

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Anaplastic Thyroid Cancer - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Anaplastic-Thyroid-Cancer-Pipeline-Review-H2-2016-2088-16220>
  
APA:
Global Markets Direct - Market Research. (2016). Anaplastic Thyroid Cancer - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Anaplastic-Thyroid-Cancer-Pipeline-Review-H2-2016-2088-16220>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.